CDSCO approves antibody cocktail drug for restricted emergency use to treat mild Covid-19 cases
CDSCO approves use of antibodies cocktail drug (Casirivimab and Imdevimab) for restricted emergency use to treat mild to moderate Covid-19 in adults and paediatric patients.
advertisement
Health workers inspect Covid-19 patients at a hospital in New Delhi. (Photo credit: PTI).
The Indian regulatory body, Central Drugs Standards Control Organisation (CDSCO), has approved the use of antibodies cocktail drug (Casirivimab and Imdevimab), for restricted emergency used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years or weighing more than at least 40 kg).
Antibodies Cocktail Drug can be a game-changer in Covid-19 treatment, especially when these are recommended to be given at the early stages of laboratory-confirmed SARS-CoV-2 infection positive result. Theis is preferebly administered within 10 days of symptoms onset.